{"id":"intravenous-omeprazole","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"2-5%","effect":"Nausea"},{"rate":"2-5%","effect":"Abdominal pain"},{"rate":"1-3%","effect":"Hypomagnesemia"},{"rate":"1-2%","effect":"Vitamin B12 deficiency"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Omeprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. The intravenous formulation provides rapid onset of action for acute acid suppression in patients unable to take oral medication.","oneSentence":"Omeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:55.774Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Stress ulcer prophylaxis"},{"name":"Zollinger-Ellison syndrome"}]},"trialDetails":[{"nctId":"NCT07312370","phase":"PHASE4","title":"Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","status":"NOT_YET_RECRUITING","sponsor":"LanZhou University","startDate":"2026-04-20","conditions":"Early Gastric Cancer, Gastric Dysplasia, Gastric Neoplasms","enrollment":120},{"nctId":"NCT05582174","phase":"PHASE4","title":"PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-18","conditions":"Upper GI Bleeding, Proton Pump Inhibitors","enrollment":594},{"nctId":"NCT07399054","phase":"","title":"Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-01-15","conditions":"Stress Ulcers, Reflux Episodes","enrollment":50},{"nctId":"NCT04394663","phase":"NA","title":"High Dose Oral Omeprazole in High Risk UGIB","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2020-10-01","conditions":"GI Bleeding","enrollment":128},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT06917963","phase":"NA","title":"Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2025-04-10","conditions":"Stoma - Ileostomy, High Output Stoma, Colon Cancer","enrollment":80},{"nctId":"NCT05487235","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2022-08-17","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":57},{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":348},{"nctId":"NCT03647852","phase":"NA","title":"Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-09-01","conditions":"Henoch-Schönlein Purpura","enrollment":150},{"nctId":"NCT06561542","phase":"PHASE1","title":"A Phase I Study of LX22001 for Injection in Healthy Subjects","status":"RECRUITING","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2024-08-05","conditions":"Healthy","enrollment":70},{"nctId":"NCT04246762","phase":"PHASE1","title":"Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2021-11-16","conditions":"Rheumatoid Arthritis","enrollment":17},{"nctId":"NCT04254783","phase":"PHASE1","title":"A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-27","conditions":"Ulcerative Colitis (UC), Crohn's Disease","enrollment":20},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT03452865","phase":"PHASE3","title":"Esomeprazole to Reduce Organ Failure in Sepsis","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2020-01-28","conditions":"Sepsis, Septic Shock","enrollment":300},{"nctId":"NCT05624229","phase":"PHASE4","title":"Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-10-01","conditions":"Upper Gastrointestinal Hemorrhage","enrollment":672},{"nctId":"NCT05566405","phase":"NA","title":"The Effects of Method of Anaesthesia on the Safety and Effectiveness of Radical Retropubic Prostatectomy","status":"COMPLETED","sponsor":"Sismanoglio General Hospital","startDate":"2020-07-27","conditions":"Prostatic Neoplasm","enrollment":60},{"nctId":"NCT02197039","phase":"","title":"The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Hemorrhage","enrollment":316},{"nctId":"NCT05061563","phase":"PHASE1","title":"A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-09-30","conditions":"Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes","enrollment":14},{"nctId":"NCT02456012","phase":"PHASE4","title":"Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients","status":"COMPLETED","sponsor":"Hsiu-Chi Cheng","startDate":"2015-04","conditions":"Peptic Ulcer Hemorrhage","enrollment":268},{"nctId":"NCT02760615","phase":"PHASE4","title":"Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2016-11-01","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":""},{"nctId":"NCT04432233","phase":"PHASE4","title":"Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-06-15","conditions":"Helicobacter Pylori Infection, Intravenous Drug Usage","enrollment":60},{"nctId":"NCT01275170","phase":"PHASE1","title":"A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-28","conditions":"Infectious Disease","enrollment":49},{"nctId":"NCT01579539","phase":"PHASE3","title":"The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-06-27","conditions":"Thyroid-associated Ophthalmopathy, Dry Eye Syndrome","enrollment":18},{"nctId":"NCT01123031","phase":"PHASE4","title":"Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)","status":"WITHDRAWN","sponsor":"Changhua Christian Hospital","startDate":"2010-04","conditions":"Upper Gastrointestinal Bleeding","enrollment":""},{"nctId":"NCT04170270","phase":"EARLY_PHASE1","title":"Oral Omeprazole in Bleeding Peptic Ulcer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-11","conditions":"Bleeding Peptic Ulcer","enrollment":100},{"nctId":"NCT01822600","phase":"PHASE4","title":"The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2010-01","conditions":"Peptic Ulcer Bleeding, Hypoalbuminemia","enrollment":91},{"nctId":"NCT01517399","phase":"PHASE1","title":"Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2011-12","conditions":"Solid Tumors","enrollment":28},{"nctId":"NCT03195946","phase":"PHASE1","title":"Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2017-06-16","conditions":"Drug Reactions","enrollment":24},{"nctId":"NCT03388463","phase":"NA","title":"Single Dose Omeprazole Versus High Dose in High-risk Critically Ill Patients.","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2016-05-11","conditions":"Critical Illness","enrollment":110},{"nctId":"NCT03362281","phase":"PHASE3","title":"Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-10","conditions":"Peptic Ulcer Hemorrhage","enrollment":540},{"nctId":"NCT03362268","phase":"PHASE2","title":"IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-02","conditions":"Peptic Ulcer Hemorrhage","enrollment":180},{"nctId":"NCT00001191","phase":"PHASE2","title":"The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1983-02-03","conditions":"Gastrinoma, Zollinger Ellison Syndrome","enrollment":""},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT02157376","phase":"PHASE3","title":"Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07","conditions":"Stress Ulcer Prophylaxis","enrollment":343},{"nctId":"NCT00519519","phase":"PHASE3","title":"Optimal Dose of Omeprazole After Endoscopic Treatment of Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2004-07","conditions":"Bleeding Peptic Ulcers Disease","enrollment":126},{"nctId":"NCT02205489","phase":"PHASE4","title":"Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":58},{"nctId":"NCT02536989","phase":"PHASE4","title":"Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-03","conditions":"Peptic Ulcer, Hemorrhage","enrollment":40},{"nctId":"NCT02593448","phase":"PHASE4","title":"Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation.","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2012-03","conditions":"NIR Spectroscopy","enrollment":64},{"nctId":"NCT01591083","phase":"PHASE4","title":"The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Bleeding","enrollment":474},{"nctId":"NCT02307591","phase":"PHASE2, PHASE3","title":"Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)","status":"WITHDRAWN","sponsor":"Emergency NGO Onlus","startDate":"2014-12","conditions":"Ebola Virus Disease","enrollment":""},{"nctId":"NCT01142245","phase":"PHASE3","title":"Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-01","conditions":"Peptic Ulcer, Bleeding","enrollment":263},{"nctId":"NCT02444507","phase":"PHASE4","title":"A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product","status":"UNKNOWN","sponsor":"isRed Pharma & Biotech Research Corporation","startDate":"2015-04","conditions":"Healthy Adult Subjects","enrollment":14},{"nctId":"NCT00881413","phase":"PHASE4","title":"Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding","status":"WITHDRAWN","sponsor":"Lotung Poh-Ai Hospital","startDate":"","conditions":"Peptic Ulcer","enrollment":""},{"nctId":"NCT00247130","phase":"PHASE4","title":"Comparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer","status":"WITHDRAWN","sponsor":"Keio University","startDate":"2005-10","conditions":"Peptic Ulcers","enrollment":""},{"nctId":"NCT01069081","phase":"PHASE2","title":"Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-08","conditions":"Breast Cancer, Metastasis, Neoplasm","enrollment":94},{"nctId":"NCT02197143","phase":"PHASE4","title":"A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2013-03","conditions":"Dyspepsia","enrollment":286},{"nctId":"NCT01766050","phase":"PHASE4","title":"Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01","conditions":"Transplant Rejection","enrollment":45},{"nctId":"NCT00633035","phase":"PHASE4","title":"Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2007-09","conditions":"Ulcer","enrollment":60},{"nctId":"NCT00230516","phase":"PHASE4","title":"Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"Healthy","enrollment":100},{"nctId":"NCT00164788","phase":"PHASE2","title":"A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole","status":"TERMINATED","sponsor":"Chinese University of Hong Kong","startDate":"2004-07","conditions":"Gastrointestinal Hemorrhage","enrollment":7},{"nctId":"NCT00164931","phase":"PHASE3","title":"A Study Comparing High Dose Omeprazole Infusion Against Scheduled Second Endoscopy for Bleeding Peptic Ulcer","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2003-10","conditions":"Peptic Ulcer Hemorrhage","enrollment":240},{"nctId":"NCT00629564","phase":"PHASE4","title":"An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"GERD","enrollment":60},{"nctId":"NCT00635414","phase":"PHASE4","title":"Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-08","conditions":"GERD","enrollment":60},{"nctId":"NCT00626262","phase":"PHASE4","title":"Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-07","conditions":"Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00625495","phase":"PHASE4","title":"Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00206050","phase":"PHASE4","title":"Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT00474019","phase":"PHASE1","title":"Phase 1 Pharmacokinetics of Intravenous Nexium in Children","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Pharmacokinetics","enrollment":42},{"nctId":"NCT00838682","phase":"PHASE4","title":"Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers","status":"TERMINATED","sponsor":"The Catholic University of Korea","startDate":"2006-04","conditions":"Peptic Ulcer Hemorrhage","enrollment":106},{"nctId":"NCT00861640","phase":"PHASE4","title":"Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2009-03","conditions":"Nonvariceal Upper Gastrointestinal Bleeding","enrollment":200},{"nctId":"NCT00590928","phase":"PHASE4","title":"Gastric pH in Critically Ill Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2004-07","conditions":"Critically Ill Patients, Indication for Stress Ulcer Prophylaxis","enrollment":75},{"nctId":"NCT00164866","phase":"PHASE4","title":"Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2004-02","conditions":"Peptic Ulcer","enrollment":638},{"nctId":"NCT00471029","phase":"PHASE4","title":"Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer","status":"UNKNOWN","sponsor":"Pamela Youde Nethersole Eastern Hospital","startDate":"2005-09","conditions":"Peptic Ulcer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["iv losec"],"phase":"marketed","status":"active","brandName":"Intravenous Omeprazole","genericName":"Intravenous Omeprazole","companyName":"Kaohsiung Medical University Chung-Ho Memorial Hospital","companyId":"kaohsiung-medical-university-chung-ho-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}